These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6247117)

  • 1. [Pharmacological basis for the therapeutic use of calcium inhibitors. Part 1].
    Thuillez C; Giudicelli JF
    Coeur Med Interne; 1980; 19(1):49-59. PubMed ID: 6247117
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings: Review of the cardiovascular pharmacology of perhexiline.
    Hudak WJ; Lewis RE; Lucas RW; Kuhn WL
    Postgrad Med J; 1973 Apr; 49():Suppl 3:16-25. PubMed ID: 4202743
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pharmacologic and therapeutic perspectives on calcium inhibitors].
    Godfraind T
    Bull Mem Acad R Med Belg; 1982; 137(12):737-53. PubMed ID: 6309312
    [No Abstract]   [Full Text] [Related]  

  • 4. [BAY a 1040--a highly potent Ca ++ -antagonistic inhibitor of electro-mechanical coupling processes in mammalian myocardium].
    Fleckenstein A; Tritthart H; Döring HJ; Byon KY
    Arzneimittelforschung; 1972 Jan; 22(1):22-33. PubMed ID: 4259147
    [No Abstract]   [Full Text] [Related]  

  • 5. [Calcium antagonism as a mode of action of coronary vasodilator agents].
    Meisel P; Rohde M; Rönfanz M; Teichmann H; Fermum R
    Pharmazie; 1976 Jul; 31(7):417-31. PubMed ID: 790400
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of hexabendin on oxygen consumption, energetics and substrate metabolism of the heart. II. Studies with intravenously administered single doses].
    Kraupp O; Wolner E; Adler-Kastner L; Chirikdjian JJ; Ploszczanski B; Tuisl E
    Arzneimittelforschung; 1966 Jun; 16(6):692-7. PubMed ID: 6014577
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological studies of 3-(3,3-diphenylpropylamino)-propyl-3',4',5'-trimethoxybenzoate (PF-26), a new coronary vasodilator.
    Hatano N; Sohji Y; Kawashima K; Kaneko H
    Arzneimittelforschung; 1971 Nov; 21(11):1628-33. PubMed ID: 5172070
    [No Abstract]   [Full Text] [Related]  

  • 8. Inotropic, vasodilating and preconditioning actions of levosimendan in the heart.
    Meyer K; Schipke JD; Klocke RC; Gams E; Korbmacher B
    Thorac Cardiovasc Surg; 2008 Oct; 56(7):379-85. PubMed ID: 18810693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Parallel influence of isometric tension development and O2 consumption of isolated papillary muscles under the influence of Ca ions, adrenaline, isoproteranol and organic Ca antagonists (iproveratril, D 600, prenylamine)].
    Byon KY; Fleckenstein A
    Pflugers Arch; 1969; 312(1):R8-9. PubMed ID: 5390309
    [No Abstract]   [Full Text] [Related]  

  • 10. [Metabolic effects of various palliative drugs for coronary insufficiency].
    Deltour G
    Therapie; 1970; 25(2):293-322. PubMed ID: 4404034
    [No Abstract]   [Full Text] [Related]  

  • 11. [On the method of action of new types of coronary dilatators with simultaneous oxygen-saving myocardial effects, prenylamine and iproveratril. 2].
    Fleckenstein A; Kammermeier H; Döring HJ; Freund HJ
    Z Kreislaufforsch; 1967 Aug; 56(8):839-58. PubMed ID: 5592708
    [No Abstract]   [Full Text] [Related]  

  • 12. A pharmacological study of N-( -(p-l-hydroxypropyl)phenoxyethyl)-l-phenyl-2-aminopropane.
    Pham-Huu-Chanh ; Pinhas H; Buu-Hoï NP
    Pharmacology; 1971; 6(3):137-44. PubMed ID: 5160295
    [No Abstract]   [Full Text] [Related]  

  • 13. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers.
    Ukkonen H; Saraste M; Akkila J; Knuuti MJ; Lehikoinen P; Någren K; Lehtonen L; Voipio-Pulkki LM
    Clin Pharmacol Ther; 1997 May; 61(5):596-607. PubMed ID: 9164421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of hexabendin on oxygen consumption, energeties and substrate metabolism of the heart. II. Studies with intravenous infusions].
    Kraupp O; Wolner E; Adler-Kastner L; Chirikdjian JJ; Ploszczanski B; Tuisl E
    Arzneimittelforschung; 1966 Jun; 16(6):697-705. PubMed ID: 6014578
    [No Abstract]   [Full Text] [Related]  

  • 15. The change of intramyocardial oxygen partial pressure after acute coronary occlusion and administration of carbocromen.
    Koyama T; Scholtholt J; Nitz RE
    Arzneimittelforschung; 1972 Mar; 22(3):507-11. PubMed ID: 5067917
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects of anti-anginal and/or coronary vasodilator drugs on coronary as well as systemic hemodynamics, myocardial blood flow distribution during halothane anesthesia in dogs (author's transl)].
    Kohyama A
    Masui; 1981 Feb; 30(2):127-40. PubMed ID: 7277675
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of cardiovascular actions of CS-611, a new coronary dilator, in the dog.
    Motomura S; Satoh K; Yamashita S; Taira N
    Arzneimittelforschung; 1981; 31(8):1238-44. PubMed ID: 7197528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs.
    Damiano BP; Giardino EC; Haertlein BJ; Stump GL; Mitchell JA; Falotico R
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):300-10. PubMed ID: 7511761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Influencing of oxygen pressure in the myocardium by coronary dilators].
    Kadatz R; Diederen W
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1969; 263(1):156-9. PubMed ID: 5804228
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of AR-L 115 BS on hemodynamics, myocardial oxygen consumption and cardiac pumping efficiency.
    Hellige G; Baller D; Ensink FB; Zipfel J; Wolpers HG; Bretschneider HJ
    Arzneimittelforschung; 1981; 31(1a):155-6. PubMed ID: 7195210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.